pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Immunology · news · pharmadog
← back to Immunology
News · Immunology
996
stories
10d
J&J and Protagonist’s Icotyde improves psoriatic arthritis but AbbVie’s Skyrizi likely to reign
biospace
10d
Argenx buyout of peptide engine and Big Pharma favorite UNP could top $1B
biospace
10d
Update: FDA investigates Novartis' Zolgensma following 9 cases of tumors in treated patients
biospace
10d
Novo’s troubled cardio drug could find niche in less sick patients
biospace
10d
Liver experts finally agree on what acute-on-chronic liver failure is
stat
10d
Sanofi-backed Windward breezes toward $204M IPO to fund respiratory pipeline from China
fiercebiotech
10d
Valneva sees LimmaTech vaccine reduce Shigella infections in phase 2 test
fiercebiotech
11d
Fresh & Ready Foods LLC Recalls Fresh To You Brand Sausage, Egg & Cheese Biscuit Sandwich Due to Possible Health Risk
fda recalls
12d
Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think so
fiercebiotech
13d
‘Flying blind’: Why experts fear Treasury’s China biotech investment crackdown will backfire
fiercebiotech
13d
New evidence for ancient cannabis use
stat
13d
‘Cancer hasn't seen this molecule before’: Onchilles’ injection shows potential for solid tumors
fiercebiotech
13d
Merck, Moderna serve 99% of trial patients with mRNA vaccine as personalized shots near market
biospace
13d
Moderna’s norovirus vaccine plans in limbo in wake of phase 3 miss
fiercebiotech
13d
Merck abandons Sutro-partnered IL-2 drug in ‘routine pipeline prioritization’
fiercebiotech
14d
Ballot measures affirm divisions over abortion and transgender issues
stat
14d
Novartis confirms 9 reported cases of tumors in patients treated with Zolgensma
biospace
14d
At ASH, drugmakers to showcase early data for three-pronged cancer therapies
biopharma dive
14d
Caldera, Evommune sign China licensing deals for autoimmune drugs
endpoints
14d
T-time: British biotech pours $133M into the pot for bispecifics
biospace
14d
Evommune inks molecular glue deal worth $1.1B biobucks to fill pipeline gap
biospace
14d
Coveted metabolic gem Rhythm reportedly gets $10B offer from AstraZeneca
biospace
14d
T-Therapeutics reloads with a $133M megaround for bispecifics
biopharma dive
14d
Beyond the needle: The future of intratumoral therapy
biospace
14d
T-Therapeutics secures $133M for cancer, autoimmune TCRs
endpoints
14d
Evommune signs $1B deal with China’s Hinova to enter same molecular glue niche as Novartis
fiercebiotech
15d
Sanofi stops development of Nurix-partnered immune drug
biopharma dive
15d
AbbVie bets up to $1.47B for Nxera’s discarded IBD program
biospace
15d
Sanofi ends development of Nurix's STAT6 degrader
endpoints
15d
Amgen starts MariTide autoinjector study as pivotal readouts approach
biospace
← prev
page 3 of 34
next →